Drugs / BMS 986178
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03831295 | Mar 2019 → Oct 2021 | metastatic malignant neoplasm | Ronald Levy | Completed | No outcome recorded |
| Phase 1 | NCT03410901 | Apr 2018 → Oct 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma | Ronald Levy | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02737475 | Jun 2016 → Nov 2020 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS 986178 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03831295 ↗ |
| Known as | Anti-ox40 antibody bms-986178 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297705 ↗ |
| Action | Activate | “OX40 agonist” PMID 33148673 ↗ Nov 2020 |
| Modality | Monoclonal antibody | “a fully human OX40 agonist IgG1 mAb” PMID 33148673 ↗ Nov 2020 |
| Route | Intravenous | “Given IV, intratumoral” NCT03410901 ↗ |
| Route | Other | “Given IV, intratumoral” NCT03410901 ↗ |